Evidence map›Paper›PMID 27733636›Full record

ArticleJournal of clinical microbiology2016

Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable.

Sikhulile Moyo, Terence Mohammed, Kathleen E Wirth, Melanie Prague, Kara Bennett, Molly Pretorius Holme, Lucy Mupfumi, Philemon Sebogodi, Natasha O Moraka, Corretah Boleo and 12 more

2 registry-linked trialsAbstract readComparative Study
In one paragraph

Article in Journal of clinical microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01965470 phase4completednot on this map

Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2013 to 2018ConditionsHIVArmsCombination Prevention, Enhanced Care
NCT05048472 nacompletednot on this mapstarted 2022, after this paper: background citation

Implementation of Point of Care HIV Viral Load Monitoring to Improve Viral Load Suppression Among Children, Adolescents and Young People Living With HIV in East Africa

TypeinterventionalSponsorMRC/UVRI and LSHTM Uganda Research UnitRan2022 to 2025Enrolled956ConditionsHIV, Viral Load, Point of Care MonitoringArmsAbbott HIV-1/2 VL Point of care Device
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Clinical Outcomes in a Randomized Controlled Trial Comparing Point-of-Care With Standard Human Immunodeficiency Virus (HIV) Viral Load Monitoring in Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  7. Timeliness of Point-of-Care Viral Load Results Improves Human Immunodeficiency Virus Monitoring in Nigeria.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. "Diagnostics (Basel, Switzerland) · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sikhulile MoyoBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana sikhulilemoyo@gmail.com.ORCID 0000-0003-3821-4592
Terence MohammedBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kathleen E WirthHarvard T. H. Chan School of Public Health, Department of Epidemiology, Boston, Massachusetts, USA.
Melanie PragueHarvard T. H. Chan School of Public Health, Department of Biostatistics, Boston, Massachusetts, USA.
Kara BennettBennett Statistical Consulting, Inc., Ballston Lake, New York, USA.
Molly Pretorius HolmeBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Lucy MupfumiBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Philemon SebogodiBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Natasha O MorakaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Corretah BoleoBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Comfort N MaphorisaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Boitumelo SeraiseBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Simani GaseitsiweBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Rosemary M MusondaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Erik van WidenfeltBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Kathleen M PowisBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Tendani GaolatheBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Eric J Tchetgen TchetgenHarvard T. H. Chan School of Public Health, Department of Epidemiology, Boston, Massachusetts, USA.
Joseph M MakhemaBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Max EssexBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Shahin LockmanBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Vladimir NovitskyBotswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.

Funding

CGH CDC HHS U01 GH000447CGH CDC HHS U2G GH001911Wellcome Trust
6 · The paper itself

Abstract

Routine monitoring of HIV-1 RNA or viral load (VL) in patients on antiretroviral therapy (ART) is important, but there are multiple impediments to VL testing in resource-constrained settings. An accurate point-of-care (POC) HIV-1 VL test could alleviate many of these challenges. We compared the performance of the Cepheid Xpert HIV-1 VL assay against the laboratory-based Abbott m2000sp/m2000rt assay (Abbott assay). ART-naive individuals participating in the Botswana Combination Prevention Project in 20 communities provided EDTA-blood specimens during household surveys. Both the POC Xpert HIV-1 VL and Abbott assays were performed on specimens sampled from 277 individuals. We found a high correlation between the Xpert HIV-1 VL and Abbott assay results (r

Indexed as

Point-of-Care TestingAntiretroviral Therapy, Highly ActiveBotswanaCross-Sectional StudiesHIV-1HIV InfectionsHumansRNA, ViralRural PopulationSensitivity and SpecificitySpecimen HandlingViral LoadRNA, Viral

Identifiers

PMID27733636
PMCPMC5121399

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.